MCID: THY042
MIFTS: 28

Thymic Epithelial Tumor malady

Categories: Rare diseases

Aliases & Classifications for Thymic Epithelial Tumor

Aliases & Descriptions for Thymic Epithelial Tumor:

Name: Thymic Epithelial Tumor 50 69
Epithelial Tumor of Thymus 50
Thymoma, Adult 50

Classifications:



Summaries for Thymic Epithelial Tumor

MalaCards based summary : Thymic Epithelial Tumor, also known as epithelial tumor of thymus, is related to thymoma type a and thymoma type b. An important gene associated with Thymic Epithelial Tumor is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Hematopoietic cell lineage. The drugs Cisplatin and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include thymus, breast and heart, and related phenotype is Decreased shRNA abundance (Z-score < -2).

Related Diseases for Thymic Epithelial Tumor

Graphical network of the top 20 diseases related to Thymic Epithelial Tumor:



Diseases related to Thymic Epithelial Tumor

Symptoms & Phenotypes for Thymic Epithelial Tumor

GenomeRNAi Phenotypes related to Thymic Epithelial Tumor according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 9.28 CD99
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 9.28 KIT
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.28 KIT
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.28 CD99
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.28 CD99
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.28 CD99
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 9.28 CD99 KIT
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.28 CD99

Drugs & Therapeutics for Thymic Epithelial Tumor

Drugs for Thymic Epithelial Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
4 Liver Extracts Phase 3,Phase 1
5 pancreatic polypeptide Phase 3
6 Analgesics Phase 3,Phase 1,Phase 2
7 Adjuvants, Anesthesia Phase 3
8 Narcotics Phase 3
9 Analgesics, Opioid Phase 3
10 Anesthetics Phase 3
11 Anesthetics, General Phase 3
12 Anesthetics, Intravenous Phase 3
13 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
14 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
15 Central Nervous System Depressants Phase 3
16 Topoisomerase Inhibitors Phase 3,Phase 2
17 Etoposide phosphate Phase 3,Phase 2
18 Cola Nutraceutical Phase 3,Phase 1
19
Cyclosporine Approved, Investigational, Vet_approved Phase 2 79217-60-0, 59865-13-3 5284373 6435893
20
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
21
Melphalan Approved Phase 2 148-82-3 4053 460612
22
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
23
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
24
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
25
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
26
Busulfan Approved, Investigational Phase 2 55-98-1 2478
27
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
28
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
29
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
30
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
31
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
32
Belinostat Approved, Investigational Phase 2 866323-14-0
33
Somatostatin Approved Phase 2 38916-34-6, 51110-01-1 53481605
34
Everolimus Approved Phase 2 159351-69-6 6442177
35
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
36
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
37
Coal tar Approved Phase 1, Phase 2 8007-45-2
38
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
39
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
40
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
41
Pembrolizumab Approved Phase 2 1374853-91-4
42
nivolumab Approved Phase 2 946414-94-4
43
leucovorin Approved, Nutraceutical Phase 2 58-05-9 54575, 6560146 143
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
45
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
46
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
47
Doxil Approved June 1999 Phase 2 31703
48
Maleic acid Experimental Phase 2 110-16-7 444266
49 insulin Phase 2
50 Prednisolone acetate Phase 2

Interventional clinical trials:

(show all 43)
id Name Status NCT ID Phase
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
2 Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3
3 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2
4 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2
5 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2
6 Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Completed NCT00010257 Phase 2
7 Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Completed NCT00003283 Phase 2
8 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2
9 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Completed NCT00024076 Phase 2
10 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases Completed NCT00003662 Phase 2
11 High Dose Somatostatin Analogues in Neuroendocrine Tumors Completed NCT00990535 Phase 2
12 Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity Completed NCT01163552 Phase 2
13 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting NCT01306045 Phase 2
14 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2
15 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting NCT02810418 Phase 1, Phase 2
16 A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors Recruiting NCT03070301 Phase 2
17 Study of Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma Recruiting NCT02636556 Phase 2
18 Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting NCT01025089 Phase 2
19 Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Active, not recruiting NCT02049047 Phase 2
20 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Active, not recruiting NCT01011439 Phase 2
21 MK-3475 in Patients With Thymic Carcinoma Active, not recruiting NCT02364076 Phase 2
22 LEE011 in Neuroendocrine Tumors of Foregut Origin Active, not recruiting NCT02420691 Phase 2
23 A Study of Axitinib in Advanced Carcinoid Tumors Active, not recruiting NCT01435122 Phase 2
24 A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Active, not recruiting NCT02623127 Phase 2
25 A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Not yet recruiting NCT02607631 Phase 2
26 Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) Not yet recruiting NCT03134118 Phase 2
27 Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Suspended NCT02054104 Phase 1, Phase 2
28 CYT107 After Vaccine Treatment (Provenge) in Patients With Metastatic Hormone-Resistant Prostate Cancer Suspended NCT01881867 Phase 2
29 Paclitaxel and Cisplatin for Thymic Neoplasm Terminated NCT00818090 Phase 2
30 Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer Terminated NCT00718809 Phase 2
31 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
32 Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Completed NCT01143545 Phase 1
33 Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma Completed NCT00314873 Phase 1
34 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
35 Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies Active, not recruiting NCT01165658 Phase 1
36 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Not yet recruiting NCT02831179 Phase 1
37 Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas Terminated NCT01258868 Phase 1
38 French National Observatory of Patients With Thymic Epithelial Tumor Recruiting NCT02724696
39 Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors Recruiting NCT02146170
40 SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access Recruiting NCT02214134
41 Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer Active, not recruiting NCT00372840
42 Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Active, not recruiting NCT02062632
43 Molecular Analysis of Thoracic Malignancies Enrolling by invitation NCT01385722

Search NIH Clinical Center for Thymic Epithelial Tumor

Genetic Tests for Thymic Epithelial Tumor

Anatomical Context for Thymic Epithelial Tumor

MalaCards organs/tissues related to Thymic Epithelial Tumor:

39
Thymus, Breast, Heart

Publications for Thymic Epithelial Tumor

Articles related to Thymic Epithelial Tumor:

(show top 50) (show all 60)
id Title Authors Year
1
Occasional detection of thymic epithelial tumor 4 years after diagnosis of adult onset Still disease: A challenging case report and immuno-oncological considerations coming from pertinent literature review. ( 27603335 )
2016
2
Thymic Epithelial Tumor-Associated Cytopenia: A 10-Year Observational Study in France. ( 26768832 )
2016
3
Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor. ( 27597277 )
2016
4
Thymic Hyperplasia After Treatment of ACTH-Dependent Cushing's Syndrome Can Be Mistaken for a Thymic Epithelial Tumor. ( 27865872 )
2016
5
Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. ( 26575977 )
2016
6
Differentiating the grades of thymic epithelial tumor malignancy using textural features of intratumoral heterogeneity via (18)F-FDG PET/CT. ( 26868139 )
2016
7
Diffuse high intensity PD-L1 staining in thymic epithelial tumors. ( 25402569 )
2015
8
Erratum: Omasa M, Date H, Sozu T, Sato T, Nagai K, Yokoi K, Okamoto T, Ikeda N, Tanaka F, and Maniwa Y, and the Japanese Association for Research on the Thymus. Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: The Japanese Association for Research on the Thymus Database Study. Cancer. doi: 10.1002/cncr.29166. ( 26057775 )
2015
9
Perplexing histologic classification of thymic epithelial tumor. ( 25997137 )
2015
10
Expression of pRb and p16INK4 in human thymic epithelial tumors in relation to the presence of human polyomavirus 7. ( 26537237 )
2015
11
Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: The Japanese Association for Research on the Thymus Database Study. ( 25565590 )
2015
12
Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology. ( 24705787 )
2014
13
Difference in distribution profiles between CD163+ tumor-associated macrophages and S100+ dendritic cells in thymic epithelial tumors. ( 25499804 )
2014
14
Methylation and expression profiles of MGMT gene in thymic epithelial tumors. ( 24388682 )
2014
15
The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor: a retrospective cohort study. ( 24954359 )
2014
16
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. ( 24974848 )
2014
17
Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor. ( 23695010 )
2013
18
Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. ( 23444221 )
2013
19
STAT3 expression correlates with prognosis of thymic epithelial tumors. ( 23590999 )
2013
20
Is There a Role of Postoperative Radiation Therapy in Completely Resected Stage I/II Thymic Epithelial Tumor? ( 23091442 )
2012
21
Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems. ( 22974165 )
2012
22
NUT rearrangement is uncommon in human thymic epithelial tumors. ( 22425924 )
2012
23
Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and I^ III-tubulin in thymic epithelial tumors. ( 21289518 )
2011
24
Successful diagnosis of a combined thymic epithelial tumor by endobronchial ultrasound-guided transbronchial needle aspiration. ( 23896935 )
2011
25
Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. ( 21372220 )
2011
26
Expression of proteasome subunit I^5t in thymic epithelial tumors. ( 21836487 )
2011
27
MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma. ( 21253760 )
2011
28
Expression and mutational status of c-kit in thymic epithelial tumors. ( 20651610 )
2010
29
Thymic epithelial tumor with heart metastasis in a horse. ( 20814442 )
2010
30
CD98 expression is associated with the grade of malignancy in thymic epithelial tumors. ( 20811665 )
2010
31
Type B3 thymic epithelial tumor in an adolescent detected by immunohistochemical staining for CD5, CD99, and KIT (CD117): a case report. ( 19901887 )
2009
32
Computed tomographic findings and prognosis in thymic epithelial tumor patients. ( 18830115 )
2008
33
Absence of gene mutations in KIT-positive thymic epithelial tumors. ( 18486988 )
2008
34
Adjuvant radiotherapy for thymic epithelial tumor: treatment results and prognostic factors. ( 17762439 )
2007
35
[Correlation between MMP-2 activation and MT1-MMP mRNA expression in thymic epithelial tumors]. ( 16608644 )
2006
36
Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. ( 16762968 )
2006
37
Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. ( 16002927 )
2005
38
Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. ( 16125946 )
2005
39
Multimodality treatment program in invasive thymic epithelial tumor. ( 15685027 )
2005
40
High incidence of thymic epithelial tumors in E2F2 transgenic mice. ( 14684733 )
2004
41
Expression of cyclins D1, D3 and p27 in thymic epithelial tumors. ( 17670226 )
2004
42
KI-67 antigen expression predicts survival and correlates with histologic subtype in the WHO classification of thymic epithelial tumors. ( 15494865 )
2004
43
Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors. ( 14584061 )
2003
44
Expression of matrix metalloproteinases 2 and 7 in tumor cells correlates with the World Health Organization classification subtype and clinical stage of thymic epithelial tumors. ( 14691910 )
2003
45
Apoptosis in thymic epithelial tumors. ( 12234065 )
2002
46
Activation of matrix metalloproteinase-2 is correlated with invasiveness in thymic epithelial tumors. ( 11276020 )
2001
47
Thymic epithelial tumors can develop along two different pathogenetic pathways. ( 11696445 )
2001
48
[Correlation between clinical aggressiveness of thymic epithelial tumors and expression of tumor suppressor gene products (p53, p27)]. ( 10496046 )
1999
49
Differential expression of NGF receptors in human thymic epithelial tumors. ( 10483585 )
1999
50
p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors. ( 9852302 )
1998

Variations for Thymic Epithelial Tumor

Expression for Thymic Epithelial Tumor

Search GEO for disease gene expression data for Thymic Epithelial Tumor.

Pathways for Thymic Epithelial Tumor

Pathways related to Thymic Epithelial Tumor according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.22 CD5 KIT
2 10.94 CD5 KIT
3 10.35 CD5 KIT

GO Terms for Thymic Epithelial Tumor

Cellular components related to Thymic Epithelial Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.62 CD5 KIT

Sources for Thymic Epithelial Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....